Fate Therapeutics Stock Price on October 2, 2023
| FATE Stock | USD 3.17 0.49 18.28% |
Below is the normalized historical share price chart for Fate Therapeutics extending back to October 01, 2013. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Fate Therapeutics stands at 3.17, as last reported on the 29th of November, with the highest price reaching 3.27 and the lowest price hitting 2.68 during the day.
If you're considering investing in Fate Stock, it is important to understand the factors that can impact its price. At this point, Fate Therapeutics is risky. Fate Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0046, which denotes the company had a 0.0046% return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Fate Therapeutics, which you can use to evaluate the volatility of the firm. Please confirm Fate Therapeutics' Variance of 33.01, standard deviation of 5.75, and Mean Deviation of 4.47 to check if the risk estimate we provide is consistent with the expected return of 0.0265%.
At present, Fate Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Sale Purchase Of Stock is expected to grow to about 522.2 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 54.2 M. . The current year's Price Earnings To Growth Ratio is expected to grow to 0.06, whereas Price To Sales Ratio is forecasted to decline to 5.50. Fate Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 1st of October 2013 | 200 Day MA 4.328 | 50 Day MA 2.8844 | Beta 1.879 |
Fate |
Sharpe Ratio = 0.0046
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FATE |
Estimated Market Risk
| 5.81 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fate Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fate Therapeutics by adding Fate Therapeutics to a well-diversified portfolio.
Price Book 0.9965 | Enterprise Value Ebitda (2.59) | Price Sales 26.8494 | Shares Float 98.8 M | Wall Street Target Price 6.3077 |
Related Headline
Theseus Pharmaceuticals Headline on 24th of July 2023
Theseus Pharmaceuticals Inc is lower by 3.62 percent Monday ... by news.google.com
Theseus Pharmaceuticals Inc is lower by 3.62 percent Monday In Premarket Trading InvestorsObserver
Fate Therapeutics Valuation on October 2, 2023
It is possible to determine the worth of Fate Therapeutics on a given historical date. On October 2, 2023 Fate was worth 2.12 at the beginning of the trading date compared to the closed value of 1.92. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Fate Therapeutics stock. Still, in general, we apply an absolute valuation method to find Fate Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Fate Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Fate Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 2.18 | 2.24 | 2.11 | 2.12 | 1,374,306 | |
10/02/2023 | 2.12 | 2.12 | 1.89 | 1.92 | 1,543,766 |
| 1.90 | 1.90 | 1.76 | 1.84 | 1,814,799 |
| Backtest Fate Therapeutics | | | Fate Therapeutics History | | | Fate Therapeutics Valuation | Previous | Next |
Fate Therapeutics Trading Date Momentum on October 2, 2023
| On October 03 2023 Fate Therapeutics was traded for 1.84 at the closing time. The top price for the day was 1.90 and the lowest listed price was 1.76 . The trading volume for the day was 1.8 M. The trading history from October 3, 2023 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 4.17% . The overall trading delta against the current closing price is 3.65% . |
Fate Therapeutics Fundamentals Correlations and Trends
By evaluating Fate Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Fate Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Fate financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Fate Therapeutics Stock history
Fate Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Fate is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Fate Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Fate Therapeutics stock prices may prove useful in developing a viable investing in Fate Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 98.4 M | 54.2 M | |
| Net Loss | -253.5 M | -240.9 M |
Fate Therapeutics Quarterly Net Working Capital |
|
Fate Therapeutics Stock Technical Analysis
Fate Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Fate Therapeutics Period Price Range
Low | November 29, 2024
| High |
0.00 | 0.00 |
Fate Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Fate Therapeutics November 29, 2024 Market Strength
Market strength indicators help investors to evaluate how Fate Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Fate Therapeutics shares will generate the highest return on investment. By undertsting and applying Fate Therapeutics stock market strength indicators, traders can identify Fate Therapeutics entry and exit signals to maximize returns
Fate Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Fate Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Fate Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Fate to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0046 | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.91) | |||
| Treynor Ratio | (0.02) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |